Tech Company Financing Transactions
Lotus Tissue Repair Funding Round
Lotus Tissue Repair, based in Cambridge, secured $26 million from Third Rock Ventures and private investors.
Transaction Overview
Company Name
Announced On
6/30/2011
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Series A
Investors
Third Rock Ventures (Lead Investor) (Neil Exter)
Proceeds Purpose
Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality
Company Information
Company Status
Acquired or Merged
Industry
Medical Devices & Instruments
Mailing Address
One Mifflin Place 400
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Souza
Chief Financial Officer
James Fordyce
Chief Medical Officer
Philip Reilly
Browse more venture capital transactions:
Prev: 6/30/2011: TrafficCast International venture capital transaction
Next: 6/30/2011: Bar Harbor Biotechnology venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs